Ivonescimab for the Treatment of Thymic Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California at Davis (ucd)
Davis, California, United States
Surbhi Singhai, MDNot, yet, recruiting - University of California at Irvine (uci)
Irvine, California, United States
Zhaohui Ann Arter, MDNot, yet, recruiting - Ucla / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States
Jonathan W. GoldmanRecruiting - University of California at San Francisco (ucsf)
San Francisco, California, United States
Matthew Grubens, MDRecruiting - Dana Farber Cancer Institute
Boston, Massachusetts, United States
Jennifer Marks, MDNot, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 15 Jul 2025
- Primary completion
- 17 Jun 2027
- Completion
- 17 Jun 2028
- Last update posted
- 7 Jul 2026
- Registered enrollment
- 25
- Registry id
- NCT06980077
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.